Moderate to Severe Diabetic Foot Infection (DFI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Moderate to Severe Diabetic Foot Infection (DFI) Market Outlook

Thelansis’s “Moderate to Severe Diabetic Foot Infection (DFI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Moderate to Severe Diabetic Foot Infection treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Moderate to Severe Diabetic Foot Infection (DFI) Overview

Diabetic foot infection (DFI) is the most frequent reason for hospitalization and the primary cause of nontraumatic lower extremity amputation in individuals with diabetes mellitus. DFI is an infection affecting the soft tissues or bones below the malleoli. Clinical diagnosis of diabetic foot infections relies on identifying at least two typical signs of inflammation or purulence. These infections are categorized as mild, moderate, or severe. Typically, moderate infections (grade 3) extend more than 2 cm around the lesion, involve deep tissue abscesses, gangrene, or affect muscles, tendons, joints, or bones. In contrast, severe infections (grade 4) manifest as systemic infections with vital sign alterations like fever and hypotension. Peripheral artery disease contributes to diabetic foot infections, impairing blood flow and hindering wound healing in individuals with diabetes who may not initially perceive injuries. Consequently, moderate to severe foot infections become a heightened risk for this group. Most diabetic foot infections are polymicrobial, with aerobic gram-positive cocci, predominantly Staphylococcus species, being the most common pathogens. Diabetic foot infection can lead to the serious complication of osteomyelitis, necessitating surgical intervention. Diagnosis relies on clinical evidence, including purulent discharge from ulcers and classic signs of inflammation such as erythema, pain, tenderness, warmth, or induration. Additional indicators include unpleasant odor, necrosis, and wound healing failure despite optimal care. Prompt detection and proactive treatment of infections are crucial for managing diabetic foot complications. Moderate and severe diabetic foot infections may require intensive treatment and rehabilitation. The 5-year survival rate for individuals undergoing amputation due to diabetic foot ulcers (DFU) is believed to be less than 50%. Approximately 20% of diabetic foot patients with moderate or severe infections undergo partial foot amputation. Therefore, early detection and aggressive treatment are vital for individuals with diabetic foot problems, necessitating ongoing management, especially for moderate and severe infections.

• Diabetic foot ulcers (DFU) represent a significant and prevalent complication of diabetes, with around 2 million people developing DFUs annually in the United States. The annual incidence of foot ulcers in the diabetic population ranges from 1.9% to 4.0%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: